Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome

Clean Intermittent Self-Catheterization After Botulinum Neurotoxin Type A Injections

(2014) Thomas M. Kessler et al.   OBSTETRICS AND GYNECOLOGY

OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial

(2013) Christopher Chapple et al.   EUROPEAN UROLOGY

Botulinum Toxin A Versus Placebo for Refractory Detrusor Overactivity in Women: A Randomised Blinded Placebo-Controlled Trial of 240 Women (the RELAX Study)

(2012) Douglas G. Tincello et al.   EUROPEAN UROLOGY

OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial

(2012) Victor W. Nitti et al.   JOURNAL OF UROLOGY

Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial

(2010) Roger Dmochowski et al.   JOURNAL OF UROLOGY

Assessment of urodynamic and detrusor contractility variables in patients with overactive bladder syndrome treated with botulinum toxin-A: is incomplete bladder emptying predictable?

(2009) Arun Sahai et al.   BJU INTERNATIONAL

Outcome of a Randomized, Double-Blind, Placebo Controlled Trial of Botulinum A Toxin for Refractory Overactive Bladder

(2009) Michael K. Flynn et al.   JOURNAL OF UROLOGY

Refractory Idiopathic Urge Urinary Incontinence and Botulinum A Injection

(2008) Linda Brubaker et al.   JOURNAL OF UROLOGY